<DOC>
	<DOC>NCT00529087</DOC>
	<brief_summary>The primary purpose of the protocol is to evaluate the safety, efficacy, and tolerability of subcutaneous MOA-728 versus placebo in subjects with chronic non-malignant pain who have Opioid-Induced Constipation (OIC).</brief_summary>
	<brief_title>Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Analgesics, Opioid</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Methylnaltrexone</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>Adult outpatients with opioidinduced constipation and chronic nonmalignant pain. Taking oral, transdermal, intravenous, or subcutaneous opioids. Willingness to discontinue all prestudy laxative therapy and use only study permitted rescue laxatives. Exclusion Criteria History of chronic constipation before the initiation of opioid therapy. Other GI disorders known to affect bowel transit. Women who are pregnant, breastfeeding, or plan to become pregnant.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Opioid-Induced Constipation</keyword>
</DOC>